Biopharmaceuticals - Clinical-stage oncology and autoimmune therapeutics
Strategic Profile
The company is committed to developing high-impact and differentiated therapies, with a focus on building a robust autoimmune disease and cancer pipeline. Strategic partnerships include collaboration with Adimab, LLC for antibody discovery and optimization, and a co-development agreement with Taiho Pharmaceutical Co., Ltd for zipalertinib.
Cyborg Score Rationale
Cullinan is a cash-rich clinical-stage biotech with great autoimmune and AML T-cell research with promising catalysts for 2026. The company has strong analyst support with a "Strong Buy" average rating and a 12-month stock price target of $28.33, representing 139% upside potential.
Top Insights
Two high-priority investigational T cell engager programs, CLN-978 and CLN-049, position the company for a transformative year ahead.
Zipalertinib is in Phase 3 trial for treatment of non-small cell lung cancer patients with a co-development partner.
Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data.
Novel investigational FLT3xCD3 T cell engager (CLN-049) demonstrated promising efficacy, including multiple complete responses, in heavily pretreated all-comer population with relapsed/refractory AML.
Named Competitors
Cancer and immunotherapy programs — Clinical-stage oncology company
Cancer and immunotherapy programs — Oncology-focused biopharmaceutical company
Autoimmune and oncology therapies — Biopharmaceutical development company
Recent Developments
(Feb 2026) Announced initial CLN-049 results and development strategy for AML applications
(Dec 2025) Phase 1 data showed CLN-049 demonstrates approximately 30% complete response rate in heavily pretreated relapsed/refractory AML patients
(Oct 2025) CLN-978 demonstrated rapid and deep B cell depletion in multiple autoimmune diseases
Open the full interactive Cullinan Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.